Skip to main content
DataroomDataroom
Data room
  • Legit.Health
  • The Opportunity
    • Path to €1M ARR
    • Value Creation Since Seed
    • The outcome
  • Pitch deck
  • Cap Table
  • Product
  • Competitive landscape
  • Sales
  • Financials
  • Regulatory
  • Team
  • Trajectory & Recognition
  • The Opportunity

The Opportunity

The growth story: value created since the Seed round, and the road to €1M ARR, the milestone that opens the Series A. Legit.Health is at €401K recurring ARR (June 2026), and existing investors have already funded the path toward the Series A.

📄️ Path to €1M ARR

Legit.Health's recurring ARR is €401K (June 2026, actual). €1M ARR is the milestone that unlocks the Series A on materially stronger terms. This page lays out where we are, the named pipeline behind the number, and the commercial levers that build toward it.

📄️ Value Creation Since Seed

In the 21 months since closing the seed round (September 2024), Legit.Health has built the platform required for accelerated growth: a commercial team, new tier-1 customer logos, additional regulatory certifications, scientific output, captured grants, and operational maturity. Every foundational asset that drives the next phase is now in place.

📄️ The outcome

Legit.Health is building the category-defining clinical-intelligence layer for dermatology, as an independent company at scale. The exit thesis is not "sell early"; it is "build a must-own asset."

Previous
Legit.Health
Next
Path to €1M ARR
All the information contained in this data room is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)